| ID | 1010 |
| Name of the vaccine | Daptacel |
| Microbe | Bacteria |
| Disease name | Diphtheria |
| Name of bacteria | Corynebacterium diphtheriae |
| Type of vaccine | Inactivated |
| Nucleic acid content | DNA |
| Age | 6 weeks to 6 years |
| Description of the vaccine | Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine). |
| Name of the manufacturer | Sanofi Pasteur Limited |
| Name of the manufacturing country | Canada |
| Year of manufacture | 2002 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-positive bacillus. |
| Efficacy | In Sweden II Efficacy Trial, 3 DTaP vaccines and a whole-cell pertussis DTP vaccine were evaluated. |
| Vaccine formulation | Suspension for injection
|
| Dosage | Five doses of a 0.5 mL injection administered at 2, 4, 6 and 15-20 months of age, and at 4-6 years of age. |
| Mechanism of action | Serum diphtheria antitoxin level of 1 IU/ml provides long-term protection. |
| Route of administration | Intramuscular |
| Indications | Used to complete the immunization series in infants who have received 1 or more doses of whole-cell pertussis DTP. |
| Export | Distributed by- 466 Sanofi Pasteur Inc., USA |
| Approval | US FDA |
| Adjuvant | Aluminium phosphate |
| Repurposing | For tetanus and pertussis. |
| Side effects of vaccine | Fussiness, inconsolable crying, and decreased activity/lethargy, fever, tenderness, redness and increase in arm circumference. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT00258895 |
| Reference | https://www.fda.gov/media/74035/download |
| Other name | NA |
| Additional Links | NA
|